Navigation Links
Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association
Date:5/21/2009

Field Moving Toward Genotype-Guided Psychotropic Therapy

SAN FRANCISCO, May 21 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., President of Genomas, and Director of Genetics Research at Hartford Hospital and Simon Kung, M.D., Assistant Professor of Psychiatry at the Mayo Clinic will co-chair a symposium, "Emerging Clinical Applications of Genotype-Guided Psychotropics for Depressive Disorders," at the annual meeting of the American Psychiatric Association.

"Genotyping is at a point where it could be used to help guide therapeutic choices," said the Mayo Clinic's Dr. Kung. "It's fitting that Mayo Clinic, Genomas and Institute of Living/Hartford Hospital partnered on today's symposium since these institutions are among the true innovators in delivering personalized medicine to patients."

Papers presented at today's symposium were:

Greater Utilization of Psychiatric Services is Associated with Pharmacogenetic Variation and Metabolism Deficiencies

Gualberto Ruano, M.D., Ph.D., and John W. Goethe, M.D.

Genomas Inc. and Institute of Living/Hartford Hospital, Hartford, CT

Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic Mood Disorders Unit

Simon Kung, M.D.

Mayo Clinic, Rochester, MN

Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices

Jinger G. Hoop, M.D., M.F.A.

Medical College of Wisconsin, Milwaukee, WI

The Serotonin Transporter Gene (SLC6A4): Understanding Variability and Enhancing the Clinical Utility of Genotyping

David Mrazek, M.D.

Mayo Clinic, Rochester, MN

Dr. Ruano presented results from a study that showed a significant link between certain genetic variations and length of stay and re-hospitalization rates for patients treated for major depressive disorder (MDD). Data were obtained from the DNA of 150 psychiatric in-patients being treated for MDD with antidepressant and atypical antipsychotic medications at the Institute of Living.

"These genetic variations may contribute to a reduction in efficacy or an increase in side effects of medications," said Dr. Ruano.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company is developing and testing revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.net for more information.


'/>"/>
SOURCE Genomas
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
2. Genomas to Present at Life Sciences & Healthcare Venture Summit
3. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
4. Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy
5. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
6. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
7. The Hamner Institutes Announce Partnership With China Medical City
8. New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
9. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
10. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
11. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):